Navigation Links
Anthera Pharmaceuticals Forms Scientific Advisory Board
Date:2/5/2008

- Renowned Clinical Authorities to Advise on Development of New Drug

Candidate to Treat Autoimmune Disease -

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has appointed the first five members of its Scientific Advisory Board for A-623, a peptide fusion protein licensed from Amgen in December 2007 for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The scientific advisory board will include Jill Buyon, M.D., Betty Diamond, M.D., Kenneth Kalunian, M.D., David Wofsy, M.D., and Debra Zack, M.D., Ph.D.

"We are pleased to have recruited such an outstanding team of internationally recognized experts in the field of autoimmune disease," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "All have made significant contributions to the scientific understanding of lupus. The extraordinary magnitude of research and clinical expertise assembled on this board will be invaluable as we advance our clinical development programs for A-623."

-- Jill Buyon, M.D. is Professor of Medicine, New York University School

of Medicine and Vice Chairman of the Department of Rheumatology at NYU

Hospital for Joint Diseases.

-- Betty Diamond, M.D. is Head of The Center for Autoimmune and

Musculoskeletal Disease at the Feinstein Institute for Medical

Research and is on the faculty at Albert Einstein College of Medicine.

-- Kenneth Kalunian, M.D. is Professor of Medicine in the Division of

Rheumatology at the University of California, San Diego School of

Medicine.

-- David Wofsy, M.D. is Professor of Medicine and Microbiology/Immunology

at the University of California, San Francisco.

-- Debra Zack, M.D., Ph.D. is the Executive Director in Inflammation

Global Development
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
8. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Access Pharmaceuticals Announces $2.7 Million New Equity
10. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
11. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Oct. 23 Celator Pharmaceuticals today,announced that Scott Jackson, ... Investor Forum in San Francisco. Mr. Jackson will,provide a ... programs. The presentation will be held on Wednesday, October,29, ... of the Palace Hotel., The company is also ...
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the ongoing development activities ... McMahon, Ph.D., chairman and chief executive officer, Ronald ...
... recognizes excellence in ChIP, DNA methylation innovation ... Genpathway, Inc. announced today,that the company has ... American,Services in Drug Discovery Technologies Healthcare Innovation ... providing superior services for,chromatin immunoprecipitation (ChIP) and ...
Cached Biology Technology:Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum 2Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 3
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: